Back to Search
Start Over
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting
- Source :
- OncoImmunology; January 2021, Vol. 10 Issue: 1
- Publication Year :
- 2021
-
Abstract
- ABSTRACTChimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is hampered by limited CAR-T cell versatility and tractability and the lack of exclusive target antigens to discriminate cancerous from healthy tissues. To achieve temporal and qualitative control on CAR-T function, we engineered the Adapter CAR (AdCAR) system. AdCAR-T are redirected to surface antigens via biotin-labeled adapter molecules in the context of a specific linker structure, referred to as Linker-Label-Epitope. AdCAR-T execute highly specific and controllable effector function against a multiplicity of target antigens. In mice, AdCAR-T durably eliminate aggressive lymphoma. Importantly, AdCAR-T might prevent antigen evasion by combinatorial simultaneous or sequential targeting of multiple antigens and are capable to identify and differentially lyse cancer cells by integration of adapter molecule-mediated signals based on multiplex antigen expression profiles. In consequence the AdCAR technology enables controllable, flexible, combinatorial, and selective targeting.
Details
- Language :
- English
- ISSN :
- 21624011 and 2162402X
- Volume :
- 10
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- OncoImmunology
- Publication Type :
- Periodical
- Accession number :
- ejs58595776
- Full Text :
- https://doi.org/10.1080/2162402X.2021.2003532